Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427936 | 0.70 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL4774949 | 0.70 | KDM4E (0.35) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL1338593 | 0.69 | — | — | |
| SCHEMBL24846875 | 0.67 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL304534 | 0.67 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4ELMNACYP2C19ALDH1A1 | |
| SCHEMBL426628 | 0.67 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL24271158 | 0.65 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL19919573 | 0.63 | SMN1; SMN2 (0.41) | SMN1; SMN2CRBNTOP2ATOP2BALDH1A1 | |
| SCHEMBL4000264 | 0.63 | — | — | |
| SCHEMBL248285 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3004118-B1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2018-12-19 | — | — | EP | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-21 | — | — | US | disclosed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | disclosed |
| US-7279575-B2 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2007-10-09 | — | — | US | disclosed |
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1660475-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005014572-A1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | SMN1; SMN2 2469/4885CRBN 1229/4885KDM4E 803/4885 |
| US-20170362219-A1 | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-C]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | RIPK3, RIPK1, RIPK4 | SMN1; SMN2 3639/4885CRBN 4041/4885KDM4E 1362/4885 |
| US-10301306-B2 | Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors | RIPK3, RIPK1, RIPK4 | SMN1; SMN2 3639/4885CRBN 4041/4885KDM4E 1362/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | SMN1; SMN2 2627/4885CRBN 2667/4885KDM4E 959/4885 |
| US-20040209897-A1 | Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds | MAPKAPK2, MAP3K2, MKNK2 | SMN1; SMN2 1997/4885CRBN 3201/4885KDM4E 2767/4885 |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | PNPO, THPO, PAH | SMN1; SMN2 380/4885CRBN 1851/4885KDM4E 2737/4885 |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | SMN1; SMN2 3090/4885CRBN 1159/4885KDM4E 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.